split-banner-image

PALLAS

Closed

ANZ 1603/AFT-05/ABCSG 42/BIG 14-03: PALLAS

BCT Study Chair:

Nicholas Zdenkowski

An international clinical trial, open to both women and men diagnosed with Hormone Receptor (HR) positive, Human Epidermal Growth Factor Receptor 2 (HER2) negative, early stage breast cancer. PALLAS aims to find out if patients with early stage breast cancer could benefit from receiving 2 years of Palbociclib along with standard hormone treatment, compared with standard hormone treatment alone.

INTERNATIONAL

5361

INTERNATIONAL

Total number of trial

participants internationally

AUSTRALIA & NEW ZEALAND

434

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

INSTITUTIONS

21

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

PALLAS PUBLICATIONS

2022

Development and Validation of a Composite Biomarker Predictive of Palbociclib + Endocrine Treatment Benefit in Early Breast Cancer: PENELOPE-B and PALLAS Trials.

Loibl S, Denkert C, Liu Y, Knudsen ES, DeMichele A, Zhang Z, Teply-Szymanski J, Filipits M, Fasching PA, Gnant M, Deng S, Balic M, Rojo M, Watson M, Deshpande C, Turner N, Metzger O, Theall KP, Witkiewicz A, Valota O, Symmans WF, Mayer EL. San Antonio Breast Cancer Symposium. 2022; Abstract #PD17-05, Abstract

Adjuvant palbociclib for ER+ breast cancer (PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A preplanned analysis of the stage IIA cohort.

DeMichele A, Dueck AC, Hlauschek D, Martin M, Burstein HJ, Pfeiler G, Zdenkowski N, Wolff AC, Balic M, Miller K, Cameron DA, Balko JM, Traina TA, Czajkowska D, Metzger O, Lu DR, O;Brien P, Fesl C, Mayer EL, Gnant M, PALLAS Trial Investigators. Journal of Clinical Oncology. 2022; 40(36):#390216, Abstract

Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.

Pfeiler G, Hlauschek D, Mayer E, Deutschmann C, Kacerovsky-Strobl S, Martin M, Meisel JL, Zdenkowski N, Loibl S, Balic M, Park H, Prat A, Isaacs C, Machacek-Link J, Schurmans C, Theall K P, Fesl C, Dueck CA, DeMichele A, Gnant M. Journal of Clinical Oncology. 2022; 40(16 suppl):ASCO Abstract #518, Abstract

Treatment exposure and discontinuation in the PALbociclib coLlaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer (PALLAS/AFT-05/ABCSG-42/BIG 14-03).

Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HG, Zdenkowski N, Wette V, Miller KD, Balic M, Mayer IA, Cameron D, Winer EP, Lorenzo JJP, Lake D, Pristauz-Telsnigg G, Haddad UC, Shepher L, Iwata H, Goetz M, Cardoso F, Traina TA, Sabanathan D, Breitenstein U, Ackerl K, Metzger Filho O, Sehetner K, Solomon K, Sarra El-Abed, Puyana Theall K, Lu DR, Dueck A, Gnant M, DeMichele A. Journal of Clinical Oncology. 2022; 40(5):449-458, https://ascopubs.org/doi/abs/10.1200/JCO.21.02554?, Journal

2021

Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial.

Shinn E, Zahrieh D, DeMichele A, Zdenkowski N, Lemieux J, Mao J, Bjelic-Radisic V, Naughton M, Pfeiler G, Gelmon Km Mayer I, Egle D, Zoppoli G, Traina T, Jimienez MM, Novoa SA, Haddad T, Chan A, Ring AE, Wolff A, Lorenzo J, Sabanathan D, Burstein H, Nowecki ZI, Pristauz-Telsnigg G, Brufsky A, Bellet-Ezquerra M, Foukakis T, Novik Y, Rubovszky G, Muehlbacher K, Metzger O, Goulioti T, Law E, Partridge A, Carey L, Zoroufy A, Hlauschek D, Fesl C, Mayer E, Gnant M. SABCS 2021 2021; P4-12-01, Abstract

Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05).

Naughton MJ, Zahrieh D, Gnant M, Zdenkowski N, Lemieux J, Mao JJ, Bjelic-Radisic V, Shinn E, Balik M, Thomssen C, Neisel J, Ruiz-Echarri M, Loibl S, Isaacs C, Cameron D, Carrasco FMH, Goetz M, Wette V, Werutsky G, Rugo H, Vetter M, Tseng L-M, Miller K, Fitzal F, Gil Gil JM, Park H, Linderholm B, Bajetta E, Dayao Z, Prat A, Ehrhardt K, Metzger O, Arahmani A, Law E, Partridge A, Carey L, Zoroufy A, Dueck A, Hlauschek D, DeMichele A, Mayer E. SABCS 2021; P4-10-01, Abstract